Skip to content

Steroids Helping Albuterol Responders Exclusively

Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00798616
Acronym
SHARE
Enrollment
0
Registered
2008-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2014-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis

Keywords

bronchiolitis, steroids, corticosteroids, albuterol, child, infant, pediatric

Brief summary

The purpose of the study is to determine whether corticosteroids are beneficial to children with bronchiolitis whose breathing gets better after being given a breathing treatment with albuterol.

Interventions

DRUGprednisolone or methylprednisolone

either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days

DRUGplacebo

oral or IV placebo

Sponsors

University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Weeks to 24 Months
Healthy volunteers
No

Inclusion criteria

* diagnosis of bronchiolitis * Respiratory Distress Assessment Index score of 4 or more

Exclusion criteria

* prior prescription of bronchodilators or inhaled corticosteroids * birth at \<36 weeks gestation * chronic cardiac disease * chronic pulmonary disease (including asthma) * immunodeficiency * non-topical steroid use in the prior week * parents that don't understand English * baseline systolic blood pressure \>118 mmHg * home oxygen use * evidence of systemic fungal or varicella infection * bronchodilator use in the prior week * allergy to albuterol or corticosteroids

Design outcomes

Primary

MeasureTime frame
respiratory rate and respiratory distress score4 hours
length of hospitalization (actual and until meets ready for discharge criteria)variable, likely no more than 2 weeks

Secondary

MeasureTime frame
number of doses of bronchodilators used during hospitalizationvariable, likely no more than 2 weeks
total duration of symptomsvariable, likely no more than 3 weeks
need for increased respiratory support (intubation, CPAP, BiPAP)variable, likely up to 2 weeks
tachycardia and/or hypertension during hospitalizationvariable, likely no more than 2 weeks
need for unanticipated medical care after dischargevariable, likely no more than 3 weeks
amount of oxygen used during hospitalizationvariable, likely less than 2 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026